We are live on ! Find out more
SLG

Stanley-Laman Group Portfolio holdings

AUM $814M
1-Year Est. Return 40.24%
This Fund
S&P 500
This Quarter Est. Return
+3.45%
1 Year Est. Return
+40.24%
3 Year Est. Return
+82.87%
5 Year Est. Return
+77.64%
10 Year Est. Return
+275.61%
AUM
$417M
AUM Growth
+$5.01M
Cap. Flow
-$3.73M
Cap. Flow %
-0.9%
Top 10 Hldgs %
14.37%
Holding
298
New
40
Increased
72
Reduced
97
Closed
25

Top Buys

Rank Stock Value
1
P
Everpure Inc
P
+$560K
2
GRTS
Gritstone bio, Inc. Common Stock
GRTS
+$322K
3
ORTX
Orchard Therapeutics plc American Depositary Shares
ORTX
+$321K
4
PANW icon
Palo Alto Networks
PANW
+$292K
5
ESTC icon
Elastic
ESTC
+$285K

Top Sells

Rank Stock Value
1
VOO icon
Vanguard S&P 500 ETF
VOO
+$640K
2
VER
VEREIT, Inc.
VER
+$386K
3
T icon
AT&T
T
+$385K
4
LMT icon
Lockheed Martin
LMT
+$307K
5
FCN icon
FTI Consulting
FCN
+$294K

Sector Composition

Rank Sector Weight
1 Technology 18.62%
2 Industrials 16.04%
3 Healthcare 12.16%
4 Consumer Discretionary 6.59%
5 Financials 6.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BL icon
176
BlackLine
BL
$1.69B
$278K 0.07%
+5,186
New +$258K
TRU icon
177
TransUnion
TRU
$14.8B
$274K 0.07%
+3,725
New +$255K
PFPT
178
DELISTED
Proofpoint, Inc.
PFPT
$273K 0.07%
+2,274
New +$268K
EW icon
179
Edwards Lifesciences
EW
$47.6B
$271K 0.07%
+4,404
New +$266K
MORN icon
180
Morningstar
MORN
$6.56B
$271K 0.07%
+1,872
New +$258K
MYOK
181
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$264K 0.06%
+5,266
New +$256K
EXEL icon
182
Exelixis
EXEL
$13.9B
$263K 0.06%
+12,286
New +$257K
FOLD
183
DELISTED
Amicus Therapeutics
FOLD
$263K 0.06%
+21,082
New +$268K
ZBRA icon
184
Zebra Technologies
ZBRA
$12.4B
$261K 0.06%
+1,245
New +$251K
ESTC icon
185
Elastic
ESTC
$6.1B
$260K 0.06%
+3,487
New +$285K
RARE icon
186
Ultragenyx Pharmaceutical
RARE
$2.65B
$259K 0.06%
+4,080
New +$260K
LITE icon
187
Lumentum
LITE
$59.4B
$258K 0.06%
+4,829
New +$257K
XLNX
188
DELISTED
Xilinx Inc
XLNX
$258K 0.06%
+2,184
New +$255K
ISRG icon
189
Intuitive Surgical
ISRG
$121B
$257K 0.06%
+1,467
New +$251K
MDGL icon
190
Madrigal Pharmaceuticals
MDGL
$12.6B
$256K 0.06%
+2,447
New +$262K
VKTX icon
191
Viking Therapeutics
VKTX
$4.04B
$256K 0.06%
+30,815
New +$263K
ORTX
192
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$256K 0.06%
+1,828
New +$321K
LOGC
193
DELISTED
LogicBio Therapeutics, Inc. Common Stock
LOGC
$254K 0.06%
+19,530
New +$259K
ON icon
194
ON Semiconductor
ON
$33.8B
$252K 0.06%
12,487
– –
NATI
195
DELISTED
National Instruments Corp
NATI
$252K 0.06%
+5,998
New +$256K
LSXMA
196
DELISTED
Liberty Media Corporation Series A Liberty SiriusXM Common Stock
LSXMA
$248K 0.06%
+9,062
New +$251K
BLUE
197
DELISTED
bluebird bio
BLUE
$243K 0.06%
+148
New +$256K
REGN icon
198
Regeneron Pharmaceuticals
REGN
$68.8B
$237K 0.06%
+757
New +$252K
FFIV icon
199
F5
FFIV
$22.1B
$236K 0.06%
+1,623
New +$243K
VWO icon
200
Vanguard FTSE Emerging Markets ETF
VWO
$119B
$236K 0.06%
5,557
+276
+5% +$11.6K
6 7
8
9 10

Similar funds

VFG
Victory Financial Group Austin, Texas $814M AUM 18.17% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
CICI
Capital Investment Counsel Inc Raleigh, North Carolina $816M AUM 34.73% 1-Year Est. Return
UAG
United Advisor Group Cincinnati, Ohio $811M AUM 18.32% 1-Year Est. Return
PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
BC
Brio Consultants San Francisco, California $818M AUM 13.48% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Stanley-Laman Group's Q2 2019 Portfolio in Review

As of Q2 2019, Stanley-Laman Group held 298 positions worth $417M, up 1.2% from $412M the previous quarter. Its ten largest holdings account for 14% of the portfolio.

Stanley-Laman Group's Q2 2019 filing shows 40 new, 72 increased, 97 reduced and 25 closed positions. Its largest new stake was Everpure Inc: 28,689 shares worth $438K. The largest sale was Vanguard S&P 500 ETF, an estimated $640K.

By sector, the portfolio is most concentrated in Technology at 19% of assets, up from 18% a quarter earlier, followed by Industrials and Healthcare.

  • Stanley-Laman Group's largest Q2 2019 buy was Everpure Inc: 28,689 shares worth $438K.
  • Stanley-Laman Group added most to Palo Alto Networks in Q2 2019, an estimated $292K increase.
  • Stanley-Laman Group's biggest Q2 2019 reduction was Vanguard S&P 500 ETF, cutting an estimated $640K.
  • Stanley-Laman Group fully exited FTI Consulting in Q2 2019, selling an estimated $294K.
  • Stanley-Laman Group's ten largest holdings make up 14% of its $417M portfolio in Q2 2019.
  • Stanley-Laman Group opened 40 new positions and closed 25 in Q2 2019.
  • Stanley-Laman Group's portfolio value rose 1.2% quarter-over-quarter to $417M.

Based on Stanley-Laman Group's 13F filing for Q2 2019, filed 1 Aug 2019.